STOCK TITAN

Alvotech - ALVO STOCK NEWS

Welcome to our dedicated news page for Alvotech (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alvotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alvotech's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
none
Alvotech

Nasdaq:ALVO

ALVO Rankings

ALVO Stock Data

3.42B
61.57M
72.45%
6.96%
0.08%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Luxembourg
Luxembourg

About ALVO

alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house development and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a